Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females

In this randomized, double-blind, placebo-controlled trial, 9–15 year old Chinese males (n = 100) and 9–45 year old Chinese females (n = 500) from Wuzhou, Guangxi, China were randomized (1:1) to receive either quadrivalent HPV vaccine or adjuvant-containing placebo. Blood samples were obtained at day 1 and one month post-dose 3 to determine the level of vaccine-induced antibodies. Among vaccine recipients, high antibody levels were observed for each of the four HPV types and seroconversion was >96%. The vaccine was generally well tolerated, with no vaccine-related serious adverse events. This study demonstrated that the quadrivalent HPV vaccine is highly immunogenic and generally well tolerated among Chinese males and females.

► We assessed the safety and immunogenicity of an HPV vaccine in Chinese subjects. ► Among vaccine recipients, high antibody levels were observed for each of the four HPV types and seroconversion was >96%. ► The vaccine was generally well tolerated, with no vaccine-related serious adverse events.